Funder: National Institutes of Health
Due Dates: November 5, 2026 (Renewal/resubmission/revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/resubmission/revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/resubmission/revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/resubmission/revision) | January 7, 2028 (Closing date)
Funding Amounts: Up to $250,000 in direct costs annually, excluding consortium F&A costs, for up to 5 years
Summary: Supports novel cancer control and population sciences research spanning methods, epidemiology, behavior, survivorship, healthcare delivery, digital health, and implementation science.
Key Information: Basic cancer biology and development of novel cancer diagnostics or therapies are not responsive and will not be reviewed.
Description
The National Cancer Institute (NCI), part of NIH, supports this R01 program through its Division of Cancer Control and Population Sciences (DCCPS). It funds novel scientific ideas with potential to substantially advance cancer control and population sciences, including statistical and analytic methods, epidemiology and genomics, behavioral interventions, healthcare delivery, cancer survivorship, digital health and data science, and implementation science. Applications may propose clinical trials, but trials are not required.
The program promotes scientific challenges suited to reduced budgets and shorter time spans, while encouraging early-stage investigators and expanding their representation in the research portfolio. Its broader goals are to reduce cancer risk, incidence, and deaths, improve survivors’ quality of life, understand cancer’s causes and distribution, and support effective interventions and monitoring of population-level cancer trends.
